OncoMatch/Clinical Trials/NCT05270200
Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse
Is NCT05270200 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies multiple treatments including Azacitidine and Chidamide for leukemia, myeloid, acute.
Treatment: Azacitidine · Chidamide — The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–3(Limited self-care)
Demographics
Lab requirements
Blood counts
neutrophil count greater than 1.5×10/L without G-CSF; platelet count greater than 80×10/L without platelet transfusion
Kidney function
serum creatinine clearance rate is greater than 30ml/min
Liver function
bilirubin, ALT and AST all less than 3 times the upper limit of normal
bilirubin, ALT and AST were all less than 3 times the upper limit of normal; neutrophil count greater than 1.5×10/L and without G-CSF treatment; platelet count greater than 80×10/L and without platelet transfusion; serum creatinine clearance rate is greater than 30ml/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05270200 currently recruiting?
Yes, this trial is currently recruiting patients.
Is there an age limit?
Yes. Patients must be 60 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages